recombinant human egfr protein (TargetMol)
Structured Review

Recombinant Human Egfr Protein, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human egfr protein/product/TargetMol
Average 94 stars, based on 1 article reviews
Images
1) Product Images from "Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling"
Article Title: Circulating Butyrate Attenuates Cetuximab Efficacy in Colorectal Cancer Through EGFR and AMPK–Wip1 Signaling
Journal: Drug Design, Development and Therapy
doi: 10.2147/DDDT.S574116
Figure Legend Snippet: NaBu enhances EGFR signaling in KRAS-WT CRC cells. ( A ) Human phospho-kinase array of Sw48 cells treated with NaBu, showing increased phosphorylation of EGFR, AKT, and ERK1/2, and decreased phosphorylation of p53 and p38. ( B ) Heatmap representation of differential phosphorylation. ( C ) Western blot validation of p-EGFR, p-AKT, and p-ERK1/2 in KRAS-WT cells (Caco2, Sw48) treated with NaBu ± CTX. ( D ) Microscale thermophoresis (MST) analysis of EGF–EGFR binding in the presence or absence of NaBu. Enhanced binding in the presence of NaBu is reflected by a leftward shift of the binding curve and a reduced apparent dissociation constant. The inset shows representative MST time traces used for curve fitting and binding analysis. NaBu (+), presence of sodium butyrate; NaBu (−), absence of sodium butyrate.
Techniques Used: Phospho-proteomics, Western Blot, Biomarker Discovery, Microscale Thermophoresis, Binding Assay
Figure Legend Snippet: Histological and immunohistochemical analyses of in vivo models. ( A ) TUNEL and Ki67 staining of subcutaneous tumor sections from Caco2 and Sw48 xenografts. CTX markedly induced apoptosis (TUNEL) and reduced proliferation (Ki67), whereas NaBu co-treatment attenuated these effects. Scale bars = 100 μm. ( B ) H&E staining of lung sections from pulmonary metastasis models. CTX preserved alveolar architecture and reduced tumor burden, while NaBu co-treatment diminished these protective effects. Scale bars = 500 μm. ( C ) Immunohistochemical staining of subcutaneous tumors showing that NaBu increased p-EGFR and Wip1 expression, consistent with in vitro findings, whereas total EGFR levels were relatively unchanged. Scale bars = 100 μm. The square boxes in the upper-right corners indicate the regions shown at higher magnification in the insets.
Techniques Used: Immunohistochemical staining, In Vivo, TUNEL Assay, Staining, Expressing, In Vitro
Figure Legend Snippet: Human validation of p-EGFR and Wip1 expression in colorectal cancer. ( A ) Representative immunohistochemical staining of p-EGFR and Wip1 in CRC patient samples stratified by circulating butyrate levels (low vs high). Insets show higher magnification of tumor regions. The square boxes in the upper-right corners indicate the regions shown at higher magnification in the insets. ( B ) Correlation analysis of circulating butyrate concentration with H-scores of p-EGFR (left) and Wip1 (right) in 50 CRC patients, showing significant positive associations (Pearson’s correlation).
Techniques Used: Biomarker Discovery, Expressing, Immunohistochemical staining, Staining, Concentration Assay

